INTRODUCTION
Seasonal influenza results in substantial global morbidity and mortality each year [1, 2] . In people with asthma, influenza infection can exacerbate asthma symptoms, which may result in asthma attacks necessitating medical attention and in many cases hospital admission [3] .
The World Health Organization (WHO) and national immunisation programmes recommend annual influenza vaccination in people with asthma as the main prophylactic measure against influenza [4] [5] [6] . In the UK, however, vaccination rates in asthma remain well below the 75% uptake target set by the WHO [7] . This suboptimal vaccine uptake is at least in part due to uncertainty amongst people with asthma and healthcare providers around the effectiveness of influenza vaccines [8] . In the UK, suboptimal vaccine protection is partly addressed with the introduction of new vaccine formulations. Specifically, in season 2018/19 younger adults aged 18-64 belonging to an at-risk group were offered a quadrivalent inactivated vaccine (QIV) and people over 65 years old were offered adjuvanted trivalent inactivated vaccine (TIV) [9] . The QIV aims to provide better protection by including two influenza B subtypes given that influenza B affects younger age groups. The adjuvanted TIV aims to enhance the immune response in older people and improve the current suboptimal vaccine effectiveness (VE) observed from traditional TIVs [9] .
Our recent systematic review suggested that the vaccine is effective against influenza infection in asthma [8] . However, the conclusions of this review were based mainly on studies in which the overall quality was rated as low due to methodological issues related to the study design and conduct [8] . Two case-control studies published after the search date of the literature review assessed VE in individuals with asthma [10] . The first study compared Downloaded from https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciz1086/5613421 by guest on 14 November 2019 the VE between asthma and non-asthma hospitalised patients for laboratory-confirmed influenza [10] . However, there were too few patients with asthma and thus, the study was under-powered to determine the effectiveness of the influenza vaccine [10] . In the second study, the VE was assessed in children 6-59 months during four seasons by various characteristics including asthma [11] . VE of 43.3% was found in the asthma subgroup.
However, no further analyses in relation to other demographics or other characteristics related to influenza infection or the vaccination were performed for the asthma subgroup [11] .
Most national immunisation committees assess the VE based on evidence from observational studies rather than placebo randomised controlled trials, which are no longer conducted in asthma since the vaccination is now a public health recommendation for all at-risk groups such as people with asthma [12] . Thus, we employed a test-negative design (TND) casecontrol study to best determine the VE for each influenza season since it is now seen as the gold standard for generating unbiased VE estimates [13] [14] [15] [16] . In addition, the large sample size of our TND study using swab samples for multiple seasons enabled us to assess various factors that affect VE in observational studies such as asthma population characteristics and influenza circulating types and subtypes which were not assessed in previous studies due to sample size limitations [8] .
The aim of this study was to assess VE in children and adults with asthma. More specifically, the objectives of this study were to: (1) evaluate seasonal influenza VE across and in single seasons; (2) evaluate the VE against common seasonal circulating viral strains; and (3) provide VE estimates by age groups.
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METHODS
Study Design
We undertook a retrospective observational TND case-control study to evaluate influenza VE on patients that seek care for acute respiratory infection. In a TND study, cases are those testing positive for influenza and controls are those testing negative for influenza. This study included children (>6 months old) and adults who were recommended by UK immunisation guidelines to receive influenza vaccination i.e. those treated for asthma requiring continuous or repeated use of inhaled or systemic corticosteroids and/or with previous exacerbations requiring hospital admission. The study participants were identified from 223 general practices (sentinel and non-sentinel) and hospitals for acute respiratory illness from influenza season 2010/11 to 2015/16 in Scotland. Patients were swabbed and tested for influenza using the multiplex real-time polymerase chain reaction (RT-PCR) assay [17] . Patients with a positive test for influenza were classified as cases, while those with a negative test were classified as controls. In patients with more than one positive test for influenza, only the first positive test was counted as a single case. VE was estimated by comparing positivity proportions between the vaccinated and unvaccinated patients [16] .
The VE assessment in the asthma population was an objective of the Seasonal Influenza Vaccine Effectiveness (SIVE) II project [18] (see included datasets in Figure 1 ). See Supplementary Appendix 1 for details.
Exposure and Outcome Assessment
The exposure status was based on vaccination administrated between the pre-influenza season and the end of the influenza season. Individuals vaccinated from 1 September until the end of the influenza season defined the "exposed" group. Individuals with no vaccination record, being vaccinated after being tested for influenza, or vaccinated within 14 days prior to testing were also classified as the "unexposed" group [18] .
General practices who were part of the sentinel scheme obtained nasal or nasopharyngeal swabs from patients with influenza-like illness (ILI) symptoms. General Practitioners usually collected swab samples from patients presenting with ILI symptoms (independent of whether the patient has or has not been vaccinated) within seven days of date of onset of those symptoms. Each general practice collected up to five samples per week and submitted these to the West of Scotland Specialist Virology Centre (WoSSVC) [18] . Each swab sample collected in general practice sentinel settings was tested by the WoSSVC using the multiplex RT-PCR test for a range of respiratory pathogens, including influenza [18] . For non-sentinel practices or secondary care, other laboratories were involved in testing. Subtype and genetic characterisation was performed for positive influenza sentinel samples and most of nonsentinel general practice and hospital samples. Data on laboratory tests carried out in nonsentinel primary and secondary health care facilities were also collected by the ECOSS database. See Supplementary Appendix 2 for baseline characteristics description.
Statistical Analysis
Baseline characteristics of study participants were described. The relation between vaccination status and baseline characteristics was also provided for cases and controls.
Proportions and odds ratios (ORs) were used to describe differences between study groups depending on the nature of each variable. All baseline population characteristics were presented as categorical variables and the x 2 test was used to describe any association in relation to exposure or outcome. Any missing data were reported. All tests were two-tailed and results considered significant if P<0.05. See Supplementary Appendix 3 and 4 for details on unit of analysis and meta-analysis.
Primary and Secondary Analysis
Pre-specified subgroup analyses as per our published protocol included the provision of VE for influenza A and B strains per season [18] . Post-hoc analysis not specified in our protocol were also carried out in this study. Specifically, we stratified the VE by age groups in order to investigate the age where immunosenescence begins in adults.
Vaccine Effectiveness
VE and their 95% CIs were estimated using the formula VE = (1-aOR) x 100 based on adjusted OR (aOR) [18] 
Sample Size
Using data from a previous study [18] we anticipated 1454 asthma patients would be swabbed over the two seasons 2014-2016. We assumed that 582 or 40.0% (1,454*0.40) of asthma patients had been vaccinated for influenza and the number of tests positive for influenza was 218 or 15.0% (1,454*0.15), which gave an 80.0% power to detect a VE of 33.0% [18] . The study recruited 1413 patients swabbed in 2014/15 and 1670 in 2015/16.
Sample size details are provided in Supplementary Appendix 5 and statistical analyses were carried out using R Version 3.4.2 and RStudio (Version 1.0.143) [19] within the NHS Scotland data safe haven.
Ethical Considerations
The Privacy Advisory Committee of the Information Services Division, NSS, approved the linkage and the statistical analysis of the anonymised data used in this study.
Reporting
We used the Strengthening the Reporting of Observational studies in Epidemiology (STROBE) and REporting of studies Conducted using Observational Routinely-collected Data (RECORD) checklists to guide transparent reporting of this TND case-control study (See Supplementary Appendix 6 and 7) [20] [21] .
RESULTS
A total registered primary care asthma population of 1,830,772 person-years out of 194,319 people with asthma was recruited in this study over a 16-year period. These data were collected as part of the SIVE II study [18] and included a total of 5,910 swab samples taken from 5,022 asthma patients from 2010/11 to 2015/16 ( Figure 2 ). These swabs were carried out in primary or secondary care settings from people with asthma and tested for influenza with the RT-PCR test. There were 781 of 5,910 (13.2%) swabs tested positive for influenza and were classified as cases (Table 1) and (86.8%) tested negative for influenza and were classified as controls ( Figure 2 ). Patients more likely to test positive for influenza were aged 45-64 years (15.1%), lived in remote small towns (>10%), with no previous seasonal influenza vaccine (15.2%) and had a swab sample collected from a primary care setting (16.7%) ( Table 2) .
Vaccine effectiveness by season and influenza type and subtype
The VE for the commonly influenza circulating strains was estimated for each strain in each influenza season.
In 2010/11, the overall VE was high (76.1% [95%CI: 55.6-87.1]) with A/H1N1 and B predominating ( 
Pooled vaccine effectiveness by influenza type and subtype
The overall VE estimate was 54.9% (95% CI: 44.4-63.4) against influenza A and B types as it is shown by the OR provided in the random effect model (Figure 3 ). Heterogeneity for this pooled estimate was detected but it was small. A substantially low VE estimate of 29.3% (95% CI: 1.0-49.4) was detected for influenza A(H3), but no heterogeneity was found ( Figure   4 ). A higher pooled VE of 48.4% (95% CI: 19.4-66.9) was found against influenza A(H1N1) Downloaded from https://academic.oup.com/cid/advance-article-abstract/doi/10.1093/cid/ciz1086/5613421 by guest on 14 November 2019 compared to influenza A(H3). Low-to-moderate heterogeneity was observed across seasons ( Figure 5 ). The highest pooled VE of 60.8% (95% CI: 31.6-77.5) was detected for influenza B. Higher heterogeneity was also observed for the influenza B compared to other strains but it was non-significant. Unadjusted OR was used for the 2013/14 season due to zero adjusted OR. This happened due to low circulating levels of influenza B strains resulting in small to zero OR which would have prohibited the provision of any meaningful OR in the metaanalysis and a subsequent VE estimation ( Figure 6 ).
Vaccine effectiveness by age group
This analysis showed that the VE was low in those 55 years and above against influenza A subtypes (except 65-74 years old for A(H1N1)) while high VEs for influenza B were found. VE was high in children (<18 years old) with a VE of 90.5% against A(H1N1) ( Table 4 ).
DISCUSSION
During six influenza seasons influenza vaccination effectiveness was over 50% for laboratory-confirmed influenza in people with asthma. Better protection was observed during seasons with good antigenic match and against the A(H1N1) and B strains. Moderate VE was found against influenza A(H1N1) (47%) and influenza B (62%) and VE was low for influenza A(H3N2) (34%). The seasonal influenza vaccine provided protection in younger adults (aged 18-54 years old) against influenza A(H1N1), influenza A(H3) subtypes and influenza B.
The highest VE was observed in 2010/11 which was characterised by high influenza activity predominated by the influenza A(H1N1) and B strains in the UK [22] [23] . While low VE was detected in 2011/12, this is likely due to low and late activity of the predominant A(H3) strain and an antigenic vaccine mismatch [24] . Intra-seasonal VE waning and low VE against the A(H3N2) was observed in the UK and US [8, [25] [26] . This lower VE has been attributed to antigenic drift [26] . In the 2012/13 season, good protection was only found against the A(H1N1) strain; this was consistent with the findings from another UK study [27] . Antigenic drift for influenza B and VE decline for influenza A(H3N2) particularly in the second trimester following vaccination was noted during this season [27] [28] . A US study including 1,259 people with asthma reported a moderate VE of 46% in 2012/13 [8, 29] .
We found overall protection against influenza in 2013/14 where the influenza activity was low and prolonged, influenza A(H1N1) dominated and the vaccine was well matched [30] . In 2014/15, there was vaccine stain mismatch for H3N2, we observed a positive VE for influenza B similar to findings in a UK-wide study [31] . In the 2015/16 season, our finding of an overall positive VE is consistent with the VE of 55% found in a UK study [32] . The influenza A(H1N1) strain predominated and the vaccine was well matched for this subtype [33] . We also observed a high VE against influenza B despite lineage mismatch with the vaccinealso found in another study [32] .
The overall VE of 46% in children in this study was similar to a recent TND study in Canada where the VE was 43% in children [11] . However, in our study, protection was found only against the B strain while previous studies have shown also protection against A(H1N1) [34] [35] . Lower strain-specific protection was observed in older adults (aged >55 years old) and no protection was found against influenza A strains. Nevertheless, the VE decrease in >55 years old may only be indicative of immunosenescence and further better powered studies are needed to investigate this phenomenon. There is evidence that the VE in those over the age of 75 may be lower than in those age 65-74 years [36] . The mechanism for this is uncertain, but may be explained by reduced immune responsiveness to historically used influenza antigens in the most elderly [36] . Such evidence has led to the development and introduction of either adjuvanted influenza vaccines or high dose influenza vaccines in this age group. In addition, the effects of other factors such as the presence of other underlying conditions in older persons could explain the decrease in VE estimates in this age group.
The strengths of this study include the influenza diagnosis based on a test with high predictive value and reduction of any recall or misclassification bias due to documentation of vaccination and medical condition status in high quality electronic medical records [37] .
Additionally, the TND study minimised the effects of selection bias due to differential healthcare seeking behaviour between cases and controls by assessing only the prevention of the vaccine against medically-attended influenza. The inclusion of six seasons increased the power of the study allowing the provision of VE estimates for different seasons, strains and patient characteristics. Thus, this study's findings can be generalised to the wider asthma population in Scotland.
Several limitations also need to be considered in this study. The VE in this study assessed only the prevention of influenza. However, vaccinated individuals may have also been benefited by having less severe influenza illness and a subsequent lower risk of a severe asthma attack. Thus, vaccine protection provided by decrease in influenza severity cannot be quantified in this study [14, 16, 38] . Although the general practice electronic health record includes vaccinations taking place in non-general practice settings, there may be some misclassification of vaccination status. Results from the post-hoc analyses need careful interpretation since they were not pre-specified in the protocol of this study. Unmeasured confounders could still have influenced the VE estimates. Future research should assess the confounding effect on VE from TND studies. TND studies offer an elegant way to deal with selection bias related to healthcare-seeking behaviour between cases and control. However, bias may occur due to differences in healthcare seeking behaviour between vaccinated and unvaccinated patients and swab testing may also differ between vaccinated and nonvaccinated patients particularly in non-sentinel settings [39] .
This study showed that vaccination can prevent influenza in individuals with asthma presented with ILI in Scottish primary and secondary care settings. While substantial variation in VE was observed among circulating strains and age groups, protection was still observed in most subgroups. There was significant pooled VE when the A(H1N1) dominated that could be explained by the absence of vaccine mismatch over the three seasons [23, 30, 33] . While the lower pooled VE when the A(H3) dominated could be due to vaccine mismatch in most seasons and the intra-seasonal VE waning [27, 30] . Generally, the protection against the A(H3N2) is usually lower compared to A(H1N1) and B which is around 60% or even higher [40] . Thus, evidence from this study reinforces the recommendation for annual seasonal vaccination in asthma. Although, there are current developments towards universal vaccines with better potency, durability and wide protection, these vaccines may not be available for another decade [41] . Thus, monitoring of the effectiveness of current vaccines should be continued. Further adequately powered studies will be needed to monitor the effectiveness of these vaccines in groups of the population at risk of severe influenza and complications such as persons with asthma.
The findings of this study can guide research and policymakers for the provision of a more targeted and effective vaccination programme improving the current protection of the asthma population. Specifically, policy makers and clinicians should consider adjuvant vaccine or high dose influenza vaccine in people with asthma aged 55 years and above [9] . Healthcare providers and people with asthma will also have now a clearer answer regarding the value of the influenza vaccination which is prevention of influenza infection in children and adults with current asthma.
In summary, we provide compelling national evidence over a number of years that influenza vaccination substantially reduces the risk of influenza in people with asthma. There is a need for strategies to boost influenza vaccination uptake in people with asthma.
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